Anavex Life Sciences Corp. (AVXL)
NASDAQ: AVXL · Real-Time Price · USD
4.400
-0.050 (-1.12%)
At close: Dec 5, 2025, 4:00 PM EST
4.440
+0.040 (0.91%)
After-hours: Dec 5, 2025, 7:51 PM EST

Anavex Life Sciences Income Statement

Millions USD. Fiscal year is Oct - Sep.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Sep '25 Sep '24 Sep '23 Sep '22 Sep '21 2020 - 2016
Selling, General & Admin
13.9511.1612.1613.149.15
Upgrade
Research & Development
36.8139.4240.8834.5228.31
Upgrade
Operating Expenses
50.7650.5953.0547.6637.46
Upgrade
Operating Income
-50.76-50.59-53.05-47.66-37.46
Upgrade
Interest & Investment Income
4.687.326.520.950.03
Upgrade
Currency Exchange Gain (Loss)
-0.330.19-0.04-0.9-0.27
Upgrade
Other Non Operating Income (Expenses)
0.040.08-0.94-0.05
Upgrade
EBT Excluding Unusual Items
-46.38-43-47.51-47.62-37.64
Upgrade
Pretax Income
-46.38-43-47.51-47.62-37.64
Upgrade
Income Tax Expense
---0.360.27
Upgrade
Net Income
-46.38-43-47.51-47.98-37.91
Upgrade
Net Income to Common
-46.38-43-47.51-47.98-37.91
Upgrade
Shares Outstanding (Basic)
8583807770
Upgrade
Shares Outstanding (Diluted)
8583807770
Upgrade
Shares Change (YoY)
2.18%4.61%3.74%10.18%19.95%
Upgrade
EPS (Basic)
-0.54-0.52-0.60-0.62-0.54
Upgrade
EPS (Diluted)
-0.54-0.52-0.60-0.62-0.54
Upgrade
EBIT
-50.76-50.59-53.05-47.66-37.46
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.